New drug duo tested for Tough-to-Treat stomach cancers
NCT ID NCT05274048
Summary
This is an early safety study to find the right dose of two drugs, neratinib and fam-trastuzumab deruxtecan, when given together. It's for adults with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2 and have worsened after at least one prior treatment. The main goal is to see how much of the drug combination patients can tolerate and to identify side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
Contact Email: •••••@•••••
Contact
-
Stanford Cancer Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.